0001209191-12-014562.txt : 20120301
0001209191-12-014562.hdr.sgml : 20120301
20120301170841
ACCESSION NUMBER: 0001209191-12-014562
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120228
FILED AS OF DATE: 20120301
DATE AS OF CHANGE: 20120301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DERBYSHIRE ADAM C
CENTRAL INDEX KEY: 0001212669
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23265
FILM NUMBER: 12658783
MAIL ADDRESS:
STREET 1: 8540 COLONNADE CENTER DRIVE
STREET 2: SUITE 501
CITY: RALEIGH
STATE: NC
ZIP: 27615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD
CENTRAL INDEX KEY: 0001009356
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943267443
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8510 COLONNADE CENTER DRIVE
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: (919) 862-1000
MAIL ADDRESS:
STREET 1: 8510 COLONNADE CENTER DRIVE
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: SALIX HOLDINGS LTD
DATE OF NAME CHANGE: 19970807
4
1
doc4.xml
FORM 4 SUBMISSION
X0304
4
2012-02-28
0
0001009356
SALIX PHARMACEUTICALS LTD
SLXP
0001212669
DERBYSHIRE ADAM C
8510 COLONNADE CENTER DRIVE
RALEIGH
NC
27615
0
1
0
0
EVP Finance/CFO
Common Stock
2012-02-28
4
M
0
12600
4.0666
A
143738
D
Common Stock
2012-02-28
4
S
0
12600
50.09
D
131138
D
Option to Buy Common Stock
4.0666
2012-02-28
4
M
0
12600
0.00
D
2012-07-02
Common Stock
12600
0
D
Option to Buy Common Stock
17.63
2015-06-09
Common Stock
20000
20000
D
Option to Buy Common Stock
18.8733
2014-06-17
Common Stock
30000
30000
D
Option to Buy Common Stock
8.00
2013-05-30
Common Stock
90000
90000
D
The shares covered by this Form 4 have been sold pursuant to a Rule 10b5-1 Sales Plan dated December 2, 2011, which is intended to comply with Rule 10b5-1.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.34, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Options are 100% vested.
/s/ Donald R. Reynolds, by Power of Attorney
2012-03-01